Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

BACKGROUND: COVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce. Our previously published cohort study showed that methotrexate, but not targeted biologics, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahil, Satveer K, Bechman, Katie, Raharja, Antony, Domingo-Vila, Clara, Baudry, David, Brown, Matthew A, Cope, Andrew P, Dasandi, Tejus, Graham, Carl, Khan, Hataf, Lechmere, Thomas, Malim, Michael H, Meynell, Freya, Pollock, Emily, Sychowska, Kamila, Barker, Jonathan N, Norton, Sam, Galloway, James B, Doores, Katie J, Tree, Timothy, Smith, Catherine H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577228/
https://www.ncbi.nlm.nih.gov/pubmed/34778846
http://dx.doi.org/10.1016/S2665-9913(21)00333-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577228/
https://www.ncbi.nlm.nih.gov/pubmed/34778846
http://dx.doi.org/10.1016/S2665-9913(21)00333-7

Ejemplares similares